CAS 943609-66-3

Vedolizumab

CAS : 943609-66-3

Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of Crohn's disease and ulcerative colitis.

Degré de pureté : SDS-PAGE:98.4%;SEC-HPLC:99.1%

Couleur et forme : Liquid

Masse moléculaire : 146.80 kDa

Ref: TM-T9914

Vedolizumab

CAS : 943609-66-3

Inhibits lymphocyte adhesion to mucosal endothelium; Crohn's disease therapy

Degré de pureté : Min. 95%

Ref: 3D-BV165597